Terguride 0.5 mg tablet ( DrugBank: Terguride )


1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension2

86. Pulmonary arterial hypertension


Clinical trials : 1,181 Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-003975-38-AT
(EUCTR)
03/10/201028/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
99Phase 2Czech Republic;Germany;Netherlands;Austria
2EUCTR2007-003975-38-CZ
(EUCTR)
19/05/200913/02/2009Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Germany;Czech Republic;Netherlands;Austria